RxDoctor Payments DataLook up a doctor →

Joseph Payne, MD

Dermatology · Atlanta, GANPI 1831189398

Payments from drug & device makers

$721,725in general payments, 2019–2025

Across 2,302 payments — averaging $313.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$307K
  • Novartis$138K
  • UCB, Inc.$111K
  • Janssen Scientific Affairs, LLC$52K
  • Johnson & Johnson$44K
  • E.r. Squibb & Sons, L.L.C.$29K
  • plus $40K from 35 others

What the payments were for

  • Consulting fees$29,3064%
  • Speaking & faculty fees$592,03783%
  • Travel & lodging$57,6158%
  • Food & beverage$30,8054%
  • Education$8100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721,725 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$686,621
Medicare patients
581
Services billed
5,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab54$395,827
RinvoqUpadacitinib37$245,765
TremfyaGuselkumab18$240,867
AdbryTralokinumab-Ldrm30$109,316
Dupixent SyringeDupilumab14$51,660
Clobetasol Propionate87$4,284
Tacrolimus27$3,708
Minoxidil183$1,674
Doxycycline Hyclate60$1,082
Fluocinonide24$1,002
Triamcinolone Acetonide62$933
Spironolactone68$882
Dutasteride31$851
Mycophenolate Mofetil18$837
ValacyclovirValacyclovir Hcl26$769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$306,823$245,76537 claims
Johnson & JohnsonTremfya$43,746$240,86718 claims
LEO Pharma Inc.Adbry$413$109,31630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 345 dermatology providers in Georgia.

Other dermatology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →